Analyst Price Targets — CV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 4, 2025 9:17 am | — | Roth Capital | $7.00 | $4.78 | TheFly | CapsoVision resumed with a Buy at Roth Capital |
| July 28, 2025 8:32 am | Jason Wittes | Roth Capital | $6.00 | $4.00 | TheFly | CapsoVision initiated with a Buy at Roth Capital |
| May 30, 2024 11:17 am | James Quigley | Raymond James | $156.00 | $0.00 | Benzinga | Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs |
Latest News for CV
SARATOGA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (Nasdaq: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, announced the appointment of David S.
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS PR Newsw
CapsoVision NASDAQ: CV reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal imaging platform.
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CV.
U.S. House Trading
No House trades found for CV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.